RARE Stock Forecast 2025-2026
Distance to RARE Price Targets
RARE Price Momentum
10 Quality Stocks Worth Considering Now
Researching Ultragenyx (RARE) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on RARE and similar high-potential opportunities.
Latest RARE Stock Price Targets & Analyst Predictions
Based on our analysis of 31 Wall Street analysts, RARE has a bullish consensus with a median price target of $87.00 (ranging from $39.00 to $140.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $35.69, the median forecast implies a 143.8% upside. This outlook is supported by 19 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Christopher Raymond at Piper Sandler, projecting a 292.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RARE Analyst Ratings
RARE Price Target Range
Latest RARE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RARE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 27, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $117.00 |
| Mar 17, 2025 | Piper Sandler | Allison Bratzel | Overweight | Maintains | $115.00 |
| Feb 26, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $118.00 |
| Feb 18, 2025 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $136.00 |
| Feb 18, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $95.00 |
| Feb 14, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $95.00 |
| Jan 22, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $118.00 |
| Jan 13, 2025 | Piper Sandler | Christopher Raymond | Overweight | Maintains | $140.00 |
| Jan 13, 2025 | Wedbush | Laura Chico | Neutral | Reiterates | $48.00 |
| Dec 24, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $95.00 |
| Dec 20, 2024 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $88.00 |
| Nov 21, 2024 | JP Morgan | Anupam Rama | Overweight | Maintains | $102.00 |
| Nov 12, 2024 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $121.00 |
| Nov 6, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $116.00 |
| Nov 6, 2024 | RBC Capital | Luca Issi | Outperform | Reiterates | $77.00 |
| Nov 6, 2024 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $121.00 |
| Nov 6, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $95.00 |
| Oct 22, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $116.00 |
| Oct 21, 2024 | TD Cowen | Yaron Werber | Buy | Maintains | $73.00 |
| Oct 1, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $116.00 |
Ultragenyx Pharmaceutical Inc. (RARE) Competitors
The following stocks are similar to Ultragenyx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Ultragenyx Pharmaceutical Inc. (RARE) Financial Data
Ultragenyx Pharmaceutical Inc. has a market capitalization of $3.35B with a P/E ratio of -5.7x. The company generates $560.23M in trailing twelve-month revenue with a -101.6% profit margin.
Revenue growth is +29.4% quarter-over-quarter, while maintaining an operating margin of -74.2% and return on equity of -211.7%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Ultragenyx Pharmaceutical Inc. (RARE) Business Model
About Ultragenyx Pharmaceutical Inc.
Develops treatments for rare genetic diseases.
Ultragenyx Pharmaceutical Inc. develops and commercializes novel products specifically targeting rare and ultra-rare genetic diseases. The company generates revenue through the successful progression of its therapies from clinical trials to market, often collaborating with academic institutions and other pharmaceutical companies to leverage genetic information for tailored treatment solutions.
Founded in 2010 and headquartered in Novato, California, Ultragenyx is dedicated to addressing unmet medical needs in the biotechnology sector, focusing on gene therapy, small molecule drugs, and advanced biologic therapies. Its specialized approach allows it to impact niche markets that often receive less attention due to smaller patient populations.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
1,294
CEO
Dr. Emil D. Kakkis M.D., Ph.D.
Country
United States
IPO Year
2014
Website
www.ultragenyx.comUltragenyx Pharmaceutical Inc. (RARE) Latest News & Analysis
Ultragenyx reports strong revenue growth and effective cost management. Key products include Crysvita, Dojolvi, and Evkeeza. FDA's Priority Review for UX111 is set for August 2025.
Ultragenyx's strong revenue growth and diverse revenue streams enhance stability, while FDA's Priority Review for UX111 could drive future value, mitigating biotech investment risks.
Ultragenyx (RARE) shares rose significantly with above-average trading volume, though recent earnings estimate revisions may not lead to further price increases soon.
Ultragenyx's share surge and higher trading volume indicate increased investor interest, but uncertain earnings revisions suggest potential volatility ahead.
Ultragenyx Pharmaceutical granted 21,806 restricted stock units to 16 new non-executive officers as part of its Employment Inducement Plan, approved by its board on March 16, 2025.
The grant of restricted stock units to new executives indicates Ultragenyx's commitment to attracting talent, which could enhance innovation and drive future growth, affecting stock performance.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) will participate in three upcoming investor conferences, focusing on therapies for rare genetic diseases.
Ultragenyx's participation in investor conferences could signal potential growth opportunities, increased visibility, and investor interest, affecting stock performance and market perception.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) will hold its Q4 2024 earnings conference call on February 13, 2025, at 5:00 PM ET, with key executives participating.
The earnings call signals upcoming financial results, which can influence stock performance and investor sentiment surrounding Ultragenyx's future growth and potential profitability.
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
2 months agoIn 2024, the company reported total revenue of $560 million, surpassing guidance, with Crysvita® generating $410 million and Dojolvi® contributing $88 million.
Exceeding revenue guidance signals strong company performance, potentially boosting investor confidence and stock value, as it indicates effective product demand and management.
Frequently Asked Questions About RARE Stock
What is Ultragenyx Pharmaceutical Inc.'s (RARE) stock forecast for 2025?
Based on our analysis of 31 Wall Street analysts, Ultragenyx Pharmaceutical Inc. (RARE) has a median price target of $87.00. The highest price target is $140.00 and the lowest is $39.00.
Is RARE stock a good investment in 2025?
According to current analyst ratings, RARE has 19 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $35.69. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RARE stock?
Wall Street analysts predict RARE stock could reach $87.00 in the next 12 months. This represents a 143.8% increase from the current price of $35.69. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Ultragenyx Pharmaceutical Inc.'s business model?
Ultragenyx Pharmaceutical Inc. develops and commercializes novel products specifically targeting rare and ultra-rare genetic diseases. The company generates revenue through the successful progression of its therapies from clinical trials to market, often collaborating with academic institutions and other pharmaceutical companies to leverage genetic information for tailored treatment solutions.
What is the highest forecasted price for RARE Ultragenyx Pharmaceutical Inc.?
The highest price target for RARE is $140.00 from Christopher Raymond at Piper Sandler, which represents a 292.3% increase from the current price of $35.69.
What is the lowest forecasted price for RARE Ultragenyx Pharmaceutical Inc.?
The lowest price target for RARE is $39.00 from at , which represents a 9.3% increase from the current price of $35.69.
What is the overall RARE consensus from analysts for Ultragenyx Pharmaceutical Inc.?
The overall analyst consensus for RARE is bullish. Out of 31 Wall Street analysts, 19 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $87.00.
How accurate are RARE stock price projections?
Stock price projections, including those for Ultragenyx Pharmaceutical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.